| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18,2 k € | -66.7% | 54,5 k € | +33.3% | 40,9 k € | +97.6% | 20,7 k € | -56.8% | 48,0 k € | -9.5% | 53,0 k € | -4.2% | 55,4 k € | 0.0% | 55,4 k € | -8.6% | 60,6 k € | 0.0% | 60,6 k € | 0.0% | 60,6 k € | |
| Gross margin | 9,7 k € | -79.2% | 46,6 k € | +82.3% | 25,5 k € | +42.6% | 17,9 k € | -56.4% | 41,1 k € | -11.2% | 46,2 k € | -7.5% | 50,0 k € | -5.3% | 52,8 k € | -3.2% | 54,6 k € | -6.8% | 58,5 k € | -0.7% | 58,9 k € | |
| EBITDA | 9,3 k € | -79.7% | 45,8 k € | +82.1% | 25,1 k € | +43.1% | 17,6 k € | -56.5% | 40,4 k € | -12.0% | 45,9 k € | -7.6% | 49,6 k € | -5.4% | 52,5 k € | -3.2% | 54,2 k € | -6.9% | 58,2 k € | -0.7% | 58,6 k € | |
| Operating profit | 9,3 k € | +7202.3% | -131,0 € | +99.4% | -20,8 k € | +26.7% | -28,3 k € | -411.2% | -5,5 k € | -15742.9% | -35,0 € | -101.0% | 3,4 k € | -45.5% | 6,2 k € | -21.9% | 8,0 k € | -33.3% | 12,0 k € | -3.2% | 12,4 k € | |
| Profit/loss | 9,3 k € | +5860.2% | -161,0 € | +99.3% | -22,4 k € | +23.7% | -29,4 k € | -200.0% | -9,8 k € | -188.6% | -3,4 k € | -111.8% | -1,6 k € | -3126.4% | 53,0 € | -92.5% | 704,0 € | -76.7% | 3,0 k € | +1080.5% | 256,0 € | |
| Equity | -47,3 k € | +16.4% | -56,6 k € | -0.3% | -56,4 k € | -66.0% | -34,0 k € | -643.8% | -4,6 k € | -187.3% | 5,2 k € | -39.4% | 8,6 k € | -15.7% | 10,2 k € | +0.5% | 10,2 k € | +7.4% | 9,5 k € | +46.8% | 6,5 k € | |
| Total assets | 102,2 k € | -9.9% | 113,5 k € | -15.3% | 133,9 k € | -15.0% | 157,5 k € | -24.7% | 209,2 k € | -18.6% | 256,9 k € | +10.4% | 232,8 k € | -15.7% | 276,1 k € | -14.7% | 323,6 k € | -26.3% | 438,8 k € | -9.6% | 485,7 k € | |
| Cash | 205,0 € | +3316.7% | 6,0 € | -95.1% | 123,0 € | — | 0,0 € | -100.0% | 28,0 € | -77.8% | 126,0 € | -68.0% | 394,0 € | +18.0% | 334,0 € | -26.1% | 452,0 € | +22.5% | 369,0 € | |||
| Debts | 149,5 k € | -12.1% | 170,0 k € | -10.7% | 190,4 k € | -0.6% | 191,5 k € | -10.4% | 213,8 k € | -15.1% | 251,7 k € | +12.3% | 224,2 k € | -14.0% | 260,7 k € | -16.8% | 313,4 k € | -27.0% | 429,3 k € | -10.4% | 479,2 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Lubbeek · incorporated on 22/01/2014
Private company with limited liability with a balanced profile. Cash position rising (+3316.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
| Unit no. | Name | Location |
|---|---|---|
| 2226757239 | beisol pharma neerijse | Staatsbaan(LUB) 187, 3210 Lubbeek |
Beisol Pharma Neerijse is a Private company with limited liability incorporated in 2014. Its main activity is: Location-bail de propriété intellectuelle et de produits similaires, à l’exception des œuvres soumises à copyright. Its registered office is in Lubbeek.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.